ReviewMagyar onkologia2025
[The role of immunosurveillance and immunoediting in hereditary cancer predisposition syndromes].
Review in Magyar onkologia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Unveiling the gut-liver axis: the behind-the-scenes "manipulator" of human immune function.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immunosurveillance is the ability of the immune system to detect preneoplastic lesions as well as primary tumors. Immunoediting, on the other hand, includes all tumor-immune interactions and can be subdivided into three steps according to the outcome. During elimination, which can correspond to immunosurveillance, the immune system is able to eradicate immunogenic preneoplastic lesions or tumors. During the second step, the so-called equilibrium, tumors start to leverage mechanisms for immune evasion, however their growth is still controlled by the immune system. The ability of cancers to master their immune evasion efforts leads to the third step, called escape, when tumors are no longer successfully controlled by anti-tumor immunity. Hereditary cancer predisposition syndromes elevate cancer risk in a gene- and organ-specific manner. Lately, new results were uncovered regarding carcinogenic steps and pre-cancer immunity in the case of Lynch syndrome and hereditary breast and ovarian cancer syndrome, the two most frequently diagnosed cancer perdisposition syndromes. Our current review aims to summarize these novel results.
Indexed as
Identifiers
40117482PMC11929576What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.